52864-56-9 Usage
General Description
"(2-bromo-4-chlorophenyl)acetic acid" is a chemical compound belonging to the class of organic compounds known as halobenzenes. It specifically belongs to the family of phenylacetic acid derivatives. The Phenylacetic acid portion is a monocarboxylic acid comprising of an acetic acid substituting one hydrogen of the methyl group with a phenyl group. In the (2-bromo-4-chlorophenyl)acetic acid, the phenyl group in the phenylacetic derivative is substituted at the 2nd position by a bromine atom and at the 4th position by a chlorine atom. This specific structure may affect its properties and applications in different chemical reactions. It is not naturally occurring and thus, is synthesized for experimental or industrial purposes. Its physical, toxicity, and other properties are determined by scientific investigations.
Check Digit Verification of cas no
The CAS Registry Mumber 52864-56-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,2,8,6 and 4 respectively; the second part has 2 digits, 5 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 52864-56:
(7*5)+(6*2)+(5*8)+(4*6)+(3*4)+(2*5)+(1*6)=139
139 % 10 = 9
So 52864-56-9 is a valid CAS Registry Number.
InChI:InChI=1/C8H6BrClO2/c9-7-4-6(10)2-1-5(7)3-8(11)12/h1-2,4H,3H2,(H,11,12)
52864-56-9Relevant articles and documents
Phosphodiesters as GPR84 Antagonists for the Treatment of Ulcerative Colitis
Chen, Lin-Hai,Fang, You-Chen,Nan, Fa-Jun,Xiao, Yu-Feng,Xie, Xin,Zhang, Qing
, p. 3991 - 4006 (2022/03/14)
GPR84 is a proinflammatory G protein-coupled receptor associated with several inflammatory and fibrotic diseases. GPR84 antagonists have been evaluated in clinical trials to treat ulcerative colitis, idiopathic pulmonary fibrosis, and nonalcoholic steatohepatitis. However, the variety of potent and selective GPR84 antagonists is still limited. Through high-throughput screening, a novel phosphodiester compound hit 1 was identified as a GPR84 antagonist. The subsequent structural optimization led to the identification of compound 33 with improved potency in the calcium mobilization assay and the ability to inhibit the chemotaxis of neutrophils and macrophages upon GPR84 activation. In a DSS-induced mouse model of ulcerative colitis, compound 33 significantly alleviated colitis symptoms and reduced the disease activity index score at oral doses of 25 mg/kg qd, with an efficacy similar to that of positive control 5-aminosalicylic acid (200 mg/kg, qd, po), suggesting that compound 33 is a promising candidate for further drug development.
